Oppenheimer ups the price target on Verastem (VSTM) to $18 from $16 following the company's...


Oppenheimer ups the price target on Verastem (VSTM) to $18 from $16 following the company's research and development day. Analyst David Ferreiro likes the "more granular view of the cancer stem cell pipeline" on which he has an "improved outlook." Shares +2.66% premarket. (Also: Cantor likes VSTM's "panoply" of founders)

Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs